Polymer conjugates as anticancer nanomedicines

By R. Duncan. Nature Reviews. Cancer, 2006

1,862 citations recorded by the source corpus.

Subfields: Biomaterials, Biomedical Engineering, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/6b138de1384692fe30afacacafc42de3e5389918

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. O. Farokhzad
2. Jun Wu
3. Robert Langer
4. N. Bertrand
5. F. Danhier
6. Liangfang Zhang
7. N. Kamaly
8. Xiaoyang Xu

In Biomedical Engineering

1. Jun Wu
2. N. Bertrand
3. Robert Langer
4. F. Danhier
5. O. Farokhzad
6. Nicholas A. Peppas
7. Hak Soo Choi
8. N. Kamaly

In Molecular Biology

1. Jun Wu
2. O. Farokhzad
3. N. Bertrand
4. N. Kamaly
5. Xiaoyang Xu
6. F. Danhier
7. Robert Langer
8. Liangfang Zhang

Citations in the corpus

• PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. (2009, background): “Among these products, liposomal drugs [4] and polymer– drug conjugates [5] are two dominant classes, accounting for the majority of clinically approved products.”
• Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. (2014, background): “Although this product failed in phase II due to lack of efficacy [306], it was observed in humans that the ligand conferred some level of liver targeting to this polymer-drug conjugate [305].”
• Nanocarriers as an emerging platform for cancer therapy. (2007, background): “Recent reviews provide perspective on the use of nanotechnology as a fundamental tool in cancer research and nanomedicin”
• The journey of a drug-carrier in the body: an anatomo-physiological perspective. (2012, background): “conjugates [16], dendrimers [17] or other macromolecules [18]), which are in a dissolved state.”
• Nanomedicine in cancer therapy (2023, background): “283,284 The mannose receptor is a C-type lectin mainly present on the surface of macrophages, immature dendritic cells (iDCs), liver sinusoidal endothelial cells (LSECs), and tumor cells.”
• Strategies in the design of nanoparticles for therapeutic applications (2010, background): “Polymer–drug conjugates have also been extensively investigated, and several have received regulatory approva”
• Advanced Materials and Processing for Drug Delivery: The Past and the Future (2012, background): “However, subsequent analysis did show that Xyotax could improve survival rate in women although not in men [54, 64].”